Compare Fresenius Kabi Onco. with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs LUPIN - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. LUPIN FRESENIUS KABI ONCO./
LUPIN
 
P/E (TTM) x 22.1 46.7 47.4% View Chart
P/BV x 3.1 4.3 72.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   LUPIN
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
LUPIN
Mar-20
FRESENIUS KABI ONCO./
LUPIN
5-Yr Chart
Click to enlarge
High Rs176882 20.0%   
Low Rs79505 15.5%   
Sales per share (Unadj.) Rs37.7339.4 11.1%  
Earnings per share (Unadj.) Rs5.1-5.9 -85.6%  
Cash flow per share (Unadj.) Rs6.715.5 43.5%  
Dividends per share (Unadj.) Rs06.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5276.7 15.4%  
Shares outstanding (eoy) m158.23453.00 34.9%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x3.42.0 165.2%   
Avg P/E ratio x25.0-116.6 -21.4%  
P/CF ratio (eoy) x18.944.8 42.2%  
Price / Book Value ratio x3.02.5 119.3%  
Dividend payout %0-100.9 0.0%   
Avg Mkt Cap Rs m20,135314,201 6.4%   
No. of employees `0001.218.3 6.3%   
Total wages/salary Rs m70329,868 2.4%   
Avg. sales/employee Rs Th5,176.28,400.6 61.6%   
Avg. wages/employee Rs Th610.41,632.0 37.4%   
Avg. net profit/employee Rs Th699.6-147.2 -475.3%   
INCOME DATA
Net Sales Rs m5,963153,748 3.9%  
Other income Rs m184,838 0.4%   
Total revenues Rs m5,981158,585 3.8%   
Gross profit Rs m1,43024,849 5.8%  
Depreciation Rs m2589,702 2.7%   
Interest Rs m-263,630 -0.7%   
Profit before tax Rs m1,21616,355 7.4%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m-68-7,521 0.9%   
Tax Rs m34211,571 3.0%   
Profit after tax Rs m806-2,694 -29.9%  
Gross profit margin %24.016.2 148.4%  
Effective tax rate %28.170.8 39.8%   
Net profit margin %13.5-1.8 -771.3%  
BALANCE SHEET DATA
Current assets Rs m5,102154,132 3.3%   
Current liabilities Rs m2,38592,252 2.6%   
Net working cap to sales %45.640.2 113.2%  
Current ratio x2.11.7 128.0%  
Inventory Days Days15082 182.8%  
Debtors Days Days113129 87.6%  
Net fixed assets Rs m5,14889,082 5.8%   
Share capital Rs m158906 17.5%   
"Free" reserves Rs m6,556124,461 5.3%   
Net worth Rs m6,732125,367 5.4%   
Long term debt Rs m95217,933 5.3%   
Total assets Rs m10,388249,839 4.2%  
Interest coverage x-45.85.5 -831.5%   
Debt to equity ratio x0.10.1 98.9%  
Sales to assets ratio x0.60.6 93.3%   
Return on assets %7.50.4 2,004.2%  
Return on equity %12.0-2.1 -557.1%  
Return on capital %14.68.7 167.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29851,450 10.3%   
Fx outflow Rs m1,77219,470 9.1%   
Net fx Rs m3,52531,980 11.0%   
CASH FLOW
From Operations Rs m1,27414,688 8.7%  
From Investments Rs m-1,20411,070 -10.9%  
From Financial Activity Rs m-196-8,906 2.2%  
Net Cashflow Rs m-12616,853 -0.7%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 81.0 0.2 40,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 9.6 31.9 30.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   42,599 98,259 43.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TTK HEALTHCARE  ALEMBIC  DR. REDDYS LAB  ELDER PHARMA  SUVEN LIFE SCIENCES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

4 Reasons Why Sensex Surged 848 Points Today(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - GLENMARK PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS